Program
Megestrol Acetate
Also written as “Nano-crystalline Megestrol Acetate Oral Suspension”, “Megestrol acetate concentrated suspension 125 mg/mL” and “Megestrol acetate”.
Its studies are mostly in Anorexia · Cachexia · Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by 6 companies.
Drug pageMegestrol Acetate: every studyMany companies study it; this page follows only the 18 they lead. All 66 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceuticalits history only | 77 open or running | phase 4since Nov 15, 2025 | Dec 25, 2024 | Dec 31, 2026phase 4 · NCT07243379 |
| Bristol-Myers Squibbits history only | 30 open or running | phase 4since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Par Healthits history only | 30 open or running | phase 3since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Keenova Therapeuticsits history only | 20 open or running | phase 2since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Rottapharm Spainits history only | 20 open or running | phase 3since Jul 17, 2007 | Jul 17, 2007 | none ahead |
| TTY Biopharmits history only | 10 open or running | phase 2since Jul 25, 2016 | Jul 25, 2016 | none ahead |
Also a collaborator on its studies: Quintiles, Covance, SFBC Anapharm and PRA Health Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 2, 1999.
- Nov 2, 1999Phase 3 study in AnorexiaBristol-Myers Squibb · NCT00002067 · United States
- Jul 17, 2007Rottapharm Spain’s first study: phase 3 study in DementiaNew to Rottapharm SpainRottapharm Spain · NCT00503516 · 39 enrolled · Spain
- Jul 26, 2007Phase 2 study in Pulmonary Disease, Chronic ObstructiveRottapharm Spain · NCT00507949 · 40 enrolled · Spain
- Mar 11, 2008Keenova Therapeutics’ first study: phase 1 study in PharmacokineticsNew to Keenova TherapeuticsKeenova Therapeutics · NCT00638079 · 24 enrolled · Canada
- Mar 11, 2008Par Health’s first studies: 2 phase 3 studies in AnorexiaNew to Par HealthPar Health · NCT00637806, NCT00637728
- Mar 11, 2008Phase 2 study in HIV InfectionsKeenova Therapeutics · NCT00637572 · 63 enrolled · United States, India, South Africa
- Mar 11, 2008Phase 1 study in Renal InsufficiencyPar Health · NCT00637403 · 7 enrolled · United States
- Jul 25, 2016TTY Biopharm’s first study: phase 2 study in Head and Neck NeoplasmsNew to TTY BiopharmTTY Biopharm · NCT02980653 · 105 enrolled · Taiwan
- Dec 25, 2024Changchun GeneScience Pharmaceutical’s first study: phase 3 study in Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk FactorsNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT06772428 · 96 planned · China
- Feb 11, 2025No phase study in Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line TreatmentChangchun GeneScience Pharmaceutical · NCT06830018 · 76 planned · China
- Apr 29, 20252 phase 3 studiesChangchun GeneScience Pharmaceutical · NCT06961201, NCT06961188
- Aug 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungChangchun GeneScience Pharmaceutical · NCT07150663 · 134 planned · China
- Nov 15, 2025Phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaChangchun GeneScience Pharmaceutical · NCT07243379 · 495 planned · China
- Jan 4, 2026Phase 3 study in CachexiaChangchun GeneScience Pharmaceutical · NCT07356037 · 68 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaChangchun GeneScience Pharmaceutical · NCT07243379
- Dec 31, 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaChangchun GeneScience Pharmaceutical · NCT06961201
- Jun 30, 2027Primary completion: phase 3 study in CachexiaChangchun GeneScience Pharmaceutical · NCT07356037
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungChangchun GeneScience Pharmaceutical · NCT07150663
TargetBeta
“Progesterone receptor agonist”ChEMBL 37, by rule
Other programs on PGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Levonorgestrelrule | Bayer | phase 4 | 56 |
| drospirenonerule | estetra | phase 4 | 20 |
| Medroxyprogesterone Acetaterule | Pfizer | phase 4 | 11 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Utrogestanrule | calla-lily-clinical-care-ltd | phase 1 | 1 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07356037Cachexia · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 68 |
| NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia · China | 4 | Recruiting | Changchun GeneScience Pharmaceutical | Dec 31, 2026 | 495 |
| NCT07150663Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 134 |
| NCT06961201Small Cell Lung Carcinoma · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Dec 31, 2026 | 94 |
| NCT06961188Neoplasm Metastasis · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 174 |
| NCT06830018Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment · China | – | Recruiting | Changchun GeneScience Pharmaceutical | Jan 2026 | 76 |
| NCT06772428Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 96 |
| NCT02980653Head and Neck Neoplasms · Taiwan | 2 | UNKNOWN | TTY Biopharm | Aug 2017 | 105 |
| NCT00638079Pharmacokinetics · Canada | 1 | Completed | Keenova Therapeutics | Jul 2006 | 24 |
| NCT00637806Anorexia · United States | 3 | Terminated | Par Health | Sep 2006 | 4 |
| NCT00637728Anorexia · United States | 3 | Terminated | Par Health | Sep 2006 | 5 |
| NCT00637572HIV Infections · United States, India, South Africa | 2 | Completed | Keenova Therapeutics | Jun 2005 | 63 |
| NCT00637403Renal Insufficiency · United States | 1 | Terminated | Par Health | May 2006 | 7 |
| NCT00507949Pulmonary Disease, Chronic Obstructive · Spain | 2 | Completed | Rottapharm Spain | Apr 2009 | 40 |
| NCT00503516Dementia · Spain | 3 | Terminated | Rottapharm Spain | Dec 2009 | 39 |
| NCT00002345Anorexia · United States | 4 | Completed | Bristol-Myers Squibb | 40 | |
| NCT00002300Anorexia · United States | 2 | Completed | Bristol-Myers Squibb | ||
| NCT00002067Anorexia · United States | 3 | Completed | Bristol-Myers Squibb |
How it is read
Names in the registry
- “Nano-crystalline Megestrol Acetate Oral Suspension”, 5 entries
- “Megestrol acetate concentrated suspension 125 mg/mL”, 5 entries
- “Megestrol acetate”, 5 entries
- “Nanocrystalline Megestrol Acetate”, 2 entries
- “Megestrol acetate concentrated suspension 110 mg/mL”, 2 entries
Conditions, from the studies’ own filings
- Anorexia, 5 studies
- Cachexia, 2 studies
- Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.